Form 4: Kezar Life Sciences Director Micki Klearman Transactions

Micki Klearman, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options on May 11, 2026, following a merger.

Summary

• Micki Klearman, a Director at Kezar Life Sciences, Inc. (KZR), reported transactions on May 11, 2026.
• These transactions involved stock options due to a merger completed on the same date.
• Options with an exercise price of $6.955 or higher were cancelled without consideration.
• Options with an exercise price below $6.955 were converted into a cash payment and a Contingent Value Right (CVR).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details the mandatory conversion of stock options due to a merger, with both gains (cash and CVRs for in-the-money options) and losses (cancellation of out-of-the-money options).

Positives

• Director Micki Klearman's stock options that were 'in-the-money' were converted into cash and CVRs, providing value.
• The merger was completed, indicating a significant corporate event for Kezar Life Sciences.

Negatives

• Stock options with an exercise price equal to or greater than $6.955 per share were automatically cancelled and ceased to exist, resulting in no value for these options.
• The filing details the cancellation of 'out-of-the-money' options, implying a loss of potential value for those specific holdings.

Risks

• The cancellation of out-of-the-money stock options represents a loss of potential future gains for the holder.
• The value of the CVRs received for in-the-money options is contingent and not guaranteed.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions related to a completed merger.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions following significant corporate events like mergers, providing transparency to the market regarding how executive compensation and equity awards are treated.

Stakeholder Impact

• Shareholders: The merger's completion and the treatment of options will impact the overall shareholder structure and potential future value.
• Option Holders: Those holding 'in-the-money' options will receive cash and CVRs, while holders of 'out-of-the-money' options will see their awards cancelled.
• Employees: Employees who held stock options will be directly affected by the conversion terms outlined in the merger agreement.

Next Steps

• Shareholders and option holders will receive cash and CVRs for 'in-the-money' options.
• Holders of 'out-of-the-money' options will receive no consideration.

Key Dates

Keywords

Form 4, SEC Filing, Kezar Life Sciences, KZR, Micki Klearman, Stock Options, Merger, Director, Beneficial Ownership, CVR